36822-09-0Relevant articles and documents
Synthesis method of iridium-containing complex
-
, (2020/08/02)
The invention discloses a synthesis method of an iridium-containing complex. The synthesis method is characterized in that a compound Ir (La) (Lb) 2 is prepared through one-step reaction of a substance shown in the specification and La in the presence of one or more solvents or in the absence of solvents. The synthesis method is suitable for an iridium-containing complex containing two same bidentate C-N ligands and one bidentate 1, 3-diketone, 1, 3-dithione or 1, 3-diimine ligand. Compared with the traditional synthesis method, the synthesis method has higher synthesis efficiency, can be carried out under milder reaction conditions, and can realize the synthesis of some complexes which cannot be realized by the traditional method. The iridium-containing complex prepared by the synthesis method is easier to be used in production and manufacturing of organic electroluminescent devices.
DONOR-ACCEPTOR COMPOUNDS WITH NITROGEN CONTAINING HETEROPOLYAROMATICS AS THE ELECTRON ACCEPTOR
-
, (2016/10/10)
Disclosed is a light emitting substance that is used as an emitter in an organic light emitting diode. The light emitting substance includes a donor-acceptor compound having a high triplet energy heteropoly aromatic system. In other words, the donor-acceptor compound includes dibenzofuran, dibenzothiophene, and dibenzoselenophene that are electron acceptors and have multiple nitrogen atoms in one ring. The compound is represented by Chemical Formula 1 below.COPYRIGHT KIPO 2015
Synthesis and evaluation of apoptosis induction of thienopyrimidine compounds on KRAS and BRAF mutated colorectal cancer cell lines
Pedeboscq, Stephane,Pometan, Jean-Paul,Gravier, Denis,Casadebaig, Francoise,Hou, Genevieve,Gissot, Arnaud,Rey, Christophe,Ichas, Francois,Giorgi, Francesca De,Lartigue, Lydia
, p. 6724 - 6731,8 (2012/12/12)
Monoclonal antibodies (MoAb) and tyrosine kinase inhibitors (TKI) targeting the EGFR (Epidermal Growth Factor Receptor) pathways are currently used in colorectal cancer treatment. Despite the improvement of median overall survival, resistance is observed